This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cardillo, T. M. Articles by Gold, D. V. Search for Related Content PubMed PubMed Citation Articles by Cardillo, T. M. Articles by Gold, D. V.

Improved Targeting of Pancreatic Cancer

Experimental Studies of a New Bispecific Antibody, Pretargeting Enhancement System for Immunoscintigraphy

¹ Garden State Cancer Center, Belleville, and ² IBC Pharmaceutical Inc., Morris Plains, New Jersey

Purpose: The early detection and diagnosis of pancreatic cancer remains a major clinical challenge in which imaging procedures have a central role. The purpose of this study was to evaluate a pretargeting method with a bispecific PAM4 (bsPAM4; anti-MUC1) antibody for radioimmunoscintigraphy of experimental human pancreatic cancer.

Experimental Design: A bispecific F(ab')₂ antibody was generated from chimeric PAM4 Fab' and murine 734 (anti-indium-diethylenetriaminepentaacetic acid) Fab' fragments and then used in conjunction with 2 peptide haptens (¹¹¹In-IMP-156 and ^99mTc-IMP-192). Biodistribution studies and radioimmunoscintigraphic imaging properties of the radiolabeled bsPAM4, and pretargeted, radiolabeled peptides were examined in the CaPan1 human pancreatic tumor grown as s.c. xenografts in athymic nude mice. Tumor uptake and tumor:nontumor ratios were compared with a nontargeting irrelevant anti-CD20, bispecific rituximab, radiolabeled peptides alone, and with directly labeled PAM4.

Results: Biodistribution results indicated significantly greater tumor uptake of radiolabeled peptides at 3 h after injection when pretargeting was performed with bsPAM4 as compared with the bispecific rituximab [20.2 ± 5.5 percentage of injected dose per gram of tissue (%ID/g) versus 0.9 ± 0.1%ID/g, respectively, for ¹¹¹In-IMP-156, and 16.8 ± 4.8%ID/g versus 1.1 ± 0.2%ID/g, respectively, for ^99mTc-IMP-192]. Similar results were obtained at the 24-h time point. Tumor:nontumor ratios were >30 for all of the tissues except the kidneys, where a ratio of 7.8 ± 2.8 was observed. By immunoscintigraphy, tumors could be visualized as early as 30 min after injection of the radiolabeled peptide.

Conclusions: These studies demonstrate the feasibility of using the pretargeted, bispecific antibody technology for nuclear imaging of pancreatic cancer. The advantage of pretargeted bsPAM4 antibody as an imaging platform is the high specificity for pancreatic cancer as compared with the physicochemical parameters identified by current imaging technologies.

This article has been cited by other articles:

				D. V. Gold, D. M. Goldenberg, H. Karacay, E. A. Rossi, C.-H. Chang, T. M. Cardillo, W. J. McBride, and R. M. Sharkey A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma Cancer Res., June 15, 2008; 68(12): 4819 - 4826. [Abstract] [Full Text] [PDF]

				G. Liu, S. Dou, M. Rusckowski, and D. J. Hnatowich An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector Mol. Cancer Ther., May 1, 2008; 7(5): 1025 - 1032. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg, E. A. Rossi, R. M. Sharkey, W. J. McBride, and C.-H. Chang Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting J. Nucl. Med., January 1, 2008; 49(1): 158 - 163. [Abstract] [Full Text] [PDF]

				D. V. Gold, Z. Karanjawala, D. E. Modrak, D. M. Goldenberg, and R. H. Hruban PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma Clin. Cancer Res., December 15, 2007; 13(24): 7380 - 7387. [Abstract] [Full Text] [PDF]

				R. M. Sharkey, H. Karacay, W. J. McBride, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg Bispecific Antibody Pretargeting of Radionuclides for Immuno Single-Photon Emission Computed Tomography and Immuno Positron Emission Tomography Molecular Imaging: An Update Clin. Cancer Res., September 15, 2007; 13(18): 5577s - 5585s. [Abstract] [Full Text] [PDF]